SynAct Pharma AB (STO:SYNACT)

Sweden flag Sweden · Delayed Price · Currency is SEK
20.55
+0.10 (0.49%)
At close: Dec 5, 2025
80.90%
Market Cap 1.10B
Revenue (ttm) n/a
Net Income (ttm) -106.28M
Shares Out 53.33M
EPS (ttm) -2.21
PE Ratio n/a
Forward PE 76.36
Dividend n/a
Ex-Dividend Date n/a
Volume 41,783
Average Volume 94,317
Open 20.65
Previous Close 20.45
Day's Range 20.35 - 20.90
52-Week Range 8.90 - 25.30
Beta 1.14
RSI 43.13
Earnings Date Feb 18, 2026

About SynAct Pharma AB

SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency. It is also developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases.... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 6
Stock Exchange Nasdaq Stockholm
Ticker Symbol SYNACT
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.